Keybanc Maintains Overweight on Harvard Bioscience, Lowers Price Target to $7
Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $10 to $7.
81 Biggest Movers From Yesterday
Gainers
Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday.
Recap: Harvard Bioscience Q1 Earnings
Harvard Bioscience (NASDAQ:HBIO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Aldeyra Therapeutics CFO Joshua Reed To Resign; Bruce Greenberg Appointed Interim CFO
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to
Earnings Scheduled For March 8, 2022
Companies Reporting Before The Bell
• Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million.
Earnings Preview: Harvard Bioscience
Harvard Bioscience (NASDAQ:HBIO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement.
Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.10.
Earnings Outlook For Harvard Bioscience
Harvard Bioscience (NASDAQ:HBIO) is set to give its latest quarterly earnings report on Tuesday, 2022-03-08. Here's what investors need to know before the announcement.
Analysts estimate that Harvard Bioscience will report an earnings per share (EPS) of $0.10.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell
• R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.